Primary Immunodeficiency Diseases clinical trials at UC Davis

1 research study open to eligible people

Tabelecleucel in Participants with Epstein-barr Virus-associated Diseases
open to all eligible people
The purpose of this study is to assess the efficacy and safety of tabelecleucel in participants with Epstein-Barr virus (EBV) associated diseases.
Sacramento, California and other locations

Last updated: March 18, 2025